Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease)

Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease)

The cornerstone of therapy in thromboangiitis obliterans (TAO) is complete abstinence from tobacco. In addition to discontinuation of cigarette smoking, very few pharmacological and surgical options of controversial efficacy are available to date. New therapeutic options with greater efficacy are clearly needed to properly manage these patients.In this preliminary study, we assessed the effecti...

Thromboangiitis obliterans (Buerger disease)

Thromboangiitis obliterans (Buerger disease) is an occlusive, nonatherosclerotic, inflammatory vasculitis that causes ischemia in small and medium vessels. Most commonly, Buerger disease is diagnosed in 40- to 45-year-old men with a heavy smoking history. Our case exemplifies the most common presentation, diagnosis, and treatment in a 53-year-old male smoker who presents with arm pain and dusky...

Initial Evidence in Thromboangiitis Obliterans (buerger’s Disease) Treatment with Bosentan

Thromboangiitis obliterans (TAO) is a vascular disease that affects small and medium-sized arteries and veins of both upper and lower extremities. Distal ischaemic lesions and digital necrotic ulcers, as well as major amputation rates, among these patients are not negligible. So far, no treatment option has been demonstrated to be completely effective for this disease. Endothelin-1 (ET-1) has b...

Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan

BACKGROUND This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients. METHODS A clinical pilot study was designed in which patients with ulcer and/or pain at rest were treated with bosentan p.o. at a dose of 62.5 mg twice daily during the first month, which was thereafter up-titrated to 125 mg twice daily. The stu...

Treatment of thromboangiitis obliterans (Buerguer’s disease) with bosentan